- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04735835
Personalized Responses to Dietary Composition Trial 3
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Choice of design: The study is a single arm mechanistic intervention study.
Study population: The subject must have enrolled in the commercial ZOE testing program in order to apply for participation in the PREDICT 3 research program.
Screening Assessment: The study eligibility criteria listed below closely match to the commercial eligibility criteria, which ZOE users consent to before enrolling in the commercial program.
Study duration: Each participant will take part in the study for 6-14 days.
Dietary intervention: The dietary intervention will be carried out on up to 6 days with the option to continue monitoring for a total study period of 14-days. On day one, participants will be asked to fit glucose monitor. Over the following consecutive days, each participant will be instructed to eat 2 standardized meals. Participants are free to eat whatever they wish at all other times. The standardized meals will be provided to all participants by the study team via post. The foods included as part of these meals will be foods that are commonly consumed and can be made from products sold in US supermarkets. Participants will be asked to consume the entire amount of food indicated for the standardized meals and to record any left-over food via a digital app for which training will be provided at the start of the study. Following completion of standardized meal period, participants are free to eat and drink whatever they wish and will be asked to track all meals, snacks and drinks on their digital app. Participants will also be advised not to change their physical activity patterns during the course of the study.
Regular contact will be made with the participants via phone, their app and text messages for the period of the intervention to encourage compliance and answer any queries.
Anthropometry: The participant will be instructed to report height and weight.
Dietary and Lifestyle: Participants will be asked to complete a baseline questionnaire online, as well as a diet history questionnaire with portion sizes about the month preceding their study period. They will be asked to record on a daily basis their dietary, activity, and psychological data (e.g. hunger) using a digital mobile phone app. Training in all apps and equipment will be given through written and online instructions and via communications with the study support staff.
Digital devices: Participants will be asked to record daily dietary and activity information using digital apps and lifestyle information will be monitored using a wearable device. The continuous glucose monitor (Freestyle Libre, CGM) provides continuous glucose profiles for up to 14 days. The CGM will be inserted on the back of the upper arm, one day before participants begin dietary intervention. This will measure subcutaneous interstitial fluid glucose concentrations every 5 minutes. The CGM will be removed at the end of the intervention period by the participant. A contact number will be made available to participants for any inquiries or if any problems arise. Data from the CGM will be downloaded, and glucose profiles will be evaluated on the basis of data collected.
Meal responses: As a product user, the participant will consume standardized meals an additional day to the study intervention.
Blood samples: As a product user, the participant will collect postprandial blood on 1 day using finger-prick blood sampling.
Stool sample: As a product user, the participant will collect a stool sample on 1 day.
Digital app: As product users, participants will be asked to download an app designed specifically for this study, which provides diet logging functionality similar to widely used existing apps such as MyFitnessPal.
Participants will be asked to record and monitor the following information via the digital app:
- All food and drink they consume, with serving sizes and photos
- Sleep and physical activity patterns, including exercise
- Hunger and alertness ratings
- Psychological feeling of energy and mood
- Prescription and over-the-counter drug consumption
The app will be available in versions for iOS operating systems. The app will synchronize remotely with backend database servers, over an encrypted and authenticated API, and will support offline operation for when patients wish to record an entry without network coverage. This continuous background synchronization means that it will not be necessary to explicitly download data from the phone at the end of the study.
Following the 2020 pandemic of COVID-19, participants are asked to use the COVID-19 Symptom Tracker app to record their physical health symptoms, or lack thereof, attributable to COVID-19, as well as demographic and other health information to track the spread of disease in real time, and to potentially reveal risk factors for infection and severe illness.
Subcohort: An opt-in follow-on study will be offered to participants to follow dietary guidance from the ZOE app based on their PREDICT 3 results. During the first 4 weeks, participants will be given dietary guidance to follow from the ZOE app. Thereafter, for a period of up to 12 months, participants will be asked to report on outcome measures at regular intervals (monthly). Outcome measures will be reported before, during and after the 4 week period and include weight, bristol stool chart, bowel habits, hunger, energy, adherence to dietary advice, and app usage.
The data will be used to test the efficacy of the ZOE dietary advice in promoting weight loss and improvement of overall health, and may be stratified by age, sex, BMI, adherence and/or motivation to take part in the PREDICT 3 study.
Food Frequency Questionnaire Validation: A food-frequency questionnaire (FFQ) developed using the most frequently logged foods within the ZOE app will be validated against a 4-day period of food logging in the app as well as the commonly used US-based DHQ3 FFQ (target enrollment; n=100).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Meaghan Reardon
- Phone Number: 866-771-7478
- Email: meaghan@joinzoe.com
Study Contact Backup
- Name: Dan Sleeper
- Phone Number: 866-771-7478
- Email: dan@joinzoe.com
Study Locations
-
-
-
London, United Kingdom
- Recruiting
- King's College London
-
Contact:
- Inbar Linenberg
- Email: inbar@joinzoe.com
-
Contact:
- Sarah Berry
- Email: sarah.e.berry@kcl.ac.uk
-
Principal Investigator:
- Sarah E Berry, PhD
-
-
-
-
Massachusetts
-
Needham, Massachusetts, United States, 02494
- Recruiting
- Zoe US Inc.
-
Contact:
- Brad Reardon
- Phone Number: 866-771-7478
- Email: hello@joinzoe.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Enrolled in the commercial ZOE testing program
- Any sex
- Minimum 18 years of age (minimum 19 years of age in Alabama and Nebraska due to state laws)
- Body mass index (BMI) of greater than or equal to 16.5 kg/m2.
- Living in the continental US states, other than in New York (excluded from the ZOE testing product also as they are unable to access the dried blood spot service provided by Quest), or living in the UK
- Able and willing to comply with the study protocol and provide informed consent.
- Under care for chronic medical conditions (including eating disorders, type 1 diabetes, type 2 diabetes), and confirm they have checked with their primary care physician that this study is safe for them (US cohort only)
Exclusion Criteria:
- Cannot safely eat the pre-made test meals which contain standard US ingredients, e.g. due to allergy or recent gastrointestinal surgery, or are unwilling to consume these foods.
- Are pregnant.
- Have had a heart attack (myocardial infarction), stroke/transient ischemic attack (TIA), or major surgery in the last two months.
- Are unable to read and write in English, as the ZOE app is only available in English.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dietary Intervention
Dietary intervention using standardized test meals after which the postprandial metabolic response is measured.
|
To carry out a dietary intervention using standardized test meals, where the participant's postprandial response to the meal is measured and is used to predict their postprandial responses to other foods, along with input variables including metabolic profile, anthropometry, sleep and exercise.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glucose
Time Frame: 6-14 days
|
Measurement of blood glucose by continuous glucose monitor (mmol/L)
|
6-14 days
|
Gut microbiome species richness
Time Frame: 1 day
|
Species count in fecal sample (as part of ZOE testing program)
|
1 day
|
Blood Lipids
Time Frame: 1 day
|
Measurement of baseline and 6-h post-prandial triglycerides (mmol/L) by dried blood sample (as part of ZOE testing program)
|
1 day
|
Hunger and appetite assessment
Time Frame: 6-14 days
|
Self-reported in-app question on energy levels (categorical) (as part of ZOE testing program)
|
6-14 days
|
Glucose and HbA1c
Time Frame: 2 days
|
Measurement of baseline glucose (mmol/L) and HbA1c (%) by dried blood sample (as part of ZOE testing program)
|
2 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dietary assessment
Time Frame: 6-14 days
|
Weighed food log
|
6-14 days
|
Anthropometry
Time Frame: 1 day
|
Weight (kg) (as part of ZOE testing program)
|
1 day
|
Anthropometry
Time Frame: 1 day
|
Height (cm) (as part of ZOE testing program)
|
1 day
|
Dietary assessment
Time Frame: 1 month
|
Diet history and portion size questionnaire about the preceding month (as part of ZOE testing program)
|
1 month
|
Bowel Type and Habit
Time Frame: 6-14 days
|
Measurement by Bristol Stool Chart and Questionnaire (as part of ZOE testing program)
|
6-14 days
|
Perceived Energy Assessment
Time Frame: 6-14 days
|
Self-reported in-app question on energy levels (categorical) (as part of ZOE testing program)
|
6-14 days
|
Covid-19 symptom assessment
Time Frame: 6 months
|
Self-reported demographic and physical health symptoms, or lack thereof, reported on a daily basis (as part of ZOE testing program)
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence (in sub-cohort)
Time Frame: Time Frame: 12 months: Baseline, Weekly (0 to 4 weeks), monthly (5 to 52 weeks)
|
Self-reported in-app question on daily frequency of adherence (categorical)
|
Time Frame: 12 months: Baseline, Weekly (0 to 4 weeks), monthly (5 to 52 weeks)
|
Hunger (in sub-cohort)
Time Frame: Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks)
|
Self-reported in-app question on hunger levels (categorical)
|
Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks)
|
Weight (in sub-cohort)
Time Frame: Time Frame: 12 months: Baseline, Weekly (0 to 4 weeks), monthly (5 to 52 weeks)
|
Body Weight (kg)
|
Time Frame: 12 months: Baseline, Weekly (0 to 4 weeks), monthly (5 to 52 weeks)
|
Bristol Stool Category (in sub-cohort)
Time Frame: Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks)
|
Self-reported in-app Bristol Stool chart question (categorical)
|
Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks)
|
Bowel Frequency (in sub-cohort)
Time Frame: Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks)
|
Self-reported in-app question on bowel frequency
|
Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks)
|
Energy (in sub-cohort)
Time Frame: Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks)
|
Self-reported in-app question on energy levels (categorical)
|
Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks)
|
Waist Circumference (in sub-cohort)
Time Frame: Time Frame: 12 months: Baseline, monthly (4 to 52 weeks)
|
Self-reported in-app question on waist circumference
|
Time Frame: 12 months: Baseline, monthly (4 to 52 weeks)
|
Hip Circumference (in sub-cohort)
Time Frame: Time Frame: 12 months: Baseline, monthly (4 to 52 weeks)
|
Self-reported in-app question on hip circumference
|
Time Frame: 12 months: Baseline, monthly (4 to 52 weeks)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tim Spector, PhD, Zoe Global Limited
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PREDICT 3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Diseases
-
Baker Heart and Diabetes InstitutePrincess Alexandra Hospital, Brisbane, Australia; Royal Perth Hospital; Alice... and other collaboratorsRecruitingHeart Failure | Valve Heart DiseaseAustralia
-
Medical University of ViennaUnknownHeart Diseases | Heart Failure | Valvular Heart DiseaseAustria
-
Centre Chirurgical Marie LannelongueActive, not recruitingValvular Heart Disease | Valve Disease, Heart
-
Aristotle University Of ThessalonikiRecruitingCardiovascular Diseases | Heart Failure | Valvular Heart Disease | Biochemical DysfunctionGreece
-
Abiomed Inc.RecruitingHeart Diseases | Acute Decompensated Heart Failure | Congestive Heart Failure | Acute Heart FailureUnited States
-
Kathirvel SubramaniamUniversity of Maryland, Baltimore; CSL BehringRecruitingHeart Failure,Congestive | Heart Disease End StageUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Wuerzburg University HospitalRecruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseGermany
-
University of MichiganTerminatedDiastolic Heart Failure | Hypertensive Heart DiseaseUnited States
-
National Taiwan University HospitalRecruitingValve Heart DiseaseTaiwan
Clinical Trials on Dietary Intervention
-
University of ViennaCompletedEndotoxemia | Dietary HabitsAustria
-
Azienda Ospedaliero-Universitaria CareggiRecruiting
-
Brown UniversityNational Cancer Institute (NCI)UnknownUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Brown UniversityNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Josephine Ford Cancer CenterNational Cancer Institute (NCI)UnknownUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University Hospital, Strasbourg, FranceRecruitingDigestive Cancer | UndernourishedFrance
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of South CarolinaAcademy of Nutrition and DieteticsCompleted
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedCaloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast CancerBreast Carcinoma | Endometrial Carcinoma | Prostate CarcinosarcomaUnited States